Sökning: onr:"swepub:oai:DiVA.org:uu-278109" >
Clinical outcomes i...
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin : a secondary analysis of a randomized controlled trial
-
Vinereanu, Dragos (författare)
-
Stevens, Susanna R (författare)
-
Alexander, John H (författare)
-
visa fler...
-
Al-Khatib, Sana M (författare)
-
Avezum, Alvaro (författare)
-
Bahit, Marıa Cecilia (författare)
-
Granger, Christopher B (författare)
-
Lopes, Renato D (författare)
-
Halvorsen, Sigrun (författare)
-
Hanna, Michael (författare)
-
Husted, Steen (författare)
-
Hylek, Elaine M (författare)
-
Mărgulescu, Andrei D (författare)
-
- Wallentin, Lars, 1943- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper,Kardiologi
-
Atar, Dan (författare)
-
visa färre...
-
(creator_code:org_t)
- 2015-09-14
- 2015
- Engelska.
-
Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 36:46, s. 3268-
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIM: To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation.METHODS AND RESULTS: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) was a randomized, double-blind, placebo-controlled, multicentre trial that included 11 785 (64.7%) men and 6416 (35.3%) women with atrial fibrillation or flutter randomized to receive either warfarin or apixaban. The primary efficacy endpoint was stroke or systemic embolism; secondary efficacy endpoints were death from any cause and cardiovascular death. The primary safety endpoint was major bleeding; secondary safety endpoints were a composite of major bleeding and non-major clinically relevant bleeding. The risk of stroke or systemic embolism was similar in women vs. men [adjusted hazard ratio (adjHR): 0.91; 95% confidence interval (CI): 0.74-1.12; P = 0.38]. However, among patients with history of stroke or transient ischaemic attack, women had a lower risk of recurrent stroke compared with men (adjHR: 0.70; 95% CI: 0.50-0.97; P = 0.036). Women also had a lower risk of all-cause death (adjHR: 0.63; 95% CI: 0.55-0.73; P < 0.0001) and cardiovascular death (adjHR: 0.62; 95% CI: 0.51-0.75; P < 0.0001), and a trend towards less major bleeding (adjHR: 0.86; 95% CI: 0.74-1.01; P = 0.066) and major or non-major clinically relevant bleeding (adjHR: 0.89; 95% CI: 0.80-1.00; P = 0.049). The efficacy and safety benefits of apixaban compared with warfarin were consistent regardless of sex.CONCLUSION: In the ARISTOTLE trial, women had a similar rate of stroke or systemic embolism but a lower risk of mortality and less clinically relevant bleeding than men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women.TRIAL REGISTRATION: ARISTOTLE ClinicalTrials.gov number, NCT00412984.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Vinereanu, Drago ...
-
Stevens, Susanna ...
-
Alexander, John ...
-
Al-Khatib, Sana ...
-
Avezum, Alvaro
-
Bahit, Marıa Cec ...
-
visa fler...
-
Granger, Christo ...
-
Lopes, Renato D
-
Halvorsen, Sigru ...
-
Hanna, Michael
-
Husted, Steen
-
Hylek, Elaine M
-
Mărgulescu, Andr ...
-
Wallentin, Lars, ...
-
Atar, Dan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Uppsala universitet